Latest Insider Transactions at Terns Pharmaceuticals, Inc. (TERN)
This section provides a real-time view of insider transactions for Terns Pharmaceuticals, Inc. (TERN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Terns Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Terns Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 12
2024
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
476,190
+43.75%
|
$4,761,900
$10.5 P/Share
|
|
Sep 10
2024
|
Mark J. Vignola Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.81%
|
$110,000
$11.0 P/Share
|
|
Sep 10
2024
|
Mark J. Vignola Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+8.93%
|
$50,000
$5.36 P/Share
|
|
Sep 09
2024
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct |
17,235
-53.47%
|
$172,350
$10.0 P/Share
|
|
Sep 09
2024
|
Jill M. Quigley |
BUY
Exercise of conversion of derivative security
|
Direct |
17,235
+34.84%
|
$17,235
$1.82 P/Share
|
|
Aug 02
2024
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct |
8,857
-37.13%
|
$61,999
$7.5 P/Share
|
|
Aug 01
2024
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct |
6,143
-20.48%
|
$43,001
$7.68 P/Share
|
|
Jul 16
2024
|
Carl L Gordon Director |
SELL
Open market or private sale
|
Indirect |
5,188
-0.06%
|
$51,880
$10.0 P/Share
|
|
Jul 16
2024
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
5,188
-0.06%
|
$51,880
$10.0 P/Share
|
|
Jul 16
2024
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct |
400
-1.32%
|
$4,000
$10.0 P/Share
|
|
Jul 16
2024
|
Jill M. Quigley |
BUY
Exercise of conversion of derivative security
|
Direct |
400
+1.3%
|
$400
$1.82 P/Share
|
|
Jul 15
2024
|
Carl L Gordon Director |
SELL
Open market or private sale
|
Indirect |
50,976
-0.63%
|
$509,760
$10.0 P/Share
|
|
Jul 15
2024
|
Orbimed Advisors LLC Director |
SELL
Open market or private sale
|
Indirect |
50,976
-0.63%
|
$509,760
$10.0 P/Share
|
|
Jul 15
2024
|
Jill M. Quigley |
SELL
Open market or private sale
|
Direct |
14,365
-32.38%
|
$143,650
$10.0 P/Share
|
|
Jul 15
2024
|
Jill M. Quigley |
BUY
Exercise of conversion of derivative security
|
Direct |
14,365
+24.46%
|
$14,365
$1.82 P/Share
|
|
May 31
2024
|
Mark J. Vignola Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
4,791
+4.95%
|
$19,164
$4.44 P/Share
|
|
May 31
2024
|
Seokho Bryan Yoon COO and General Counsel |
BUY
Open market or private purchase
|
Direct |
4,791
+4.95%
|
$19,164
$4.44 P/Share
|
|
Apr 03
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
138,066
-1.85%
|
$828,396
$6.2 P/Share
|
|
Apr 02
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
101,480
-1.34%
|
$608,880
$6.65 P/Share
|
|
Apr 01
2024
|
Vivo Opportunity, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
181,117
-2.34%
|
$1,086,702
$6.99 P/Share
|
|
Jan 23
2024
|
Erin Quirk President, Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+50.0%
|
-
|
|
Jan 23
2024
|
Mark J. Vignola Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,750
+44.1%
|
-
|
|
Jan 23
2024
|
Seokho Bryan Yoon COO and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
68,750
+44.1%
|
-
|
|
Jan 23
2024
|
Jill M. Quigley |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+33.33%
|
-
|
|
Nov 30
2023
|
Mark J. Vignola Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
743
+3.88%
|
$2,229
$3.78 P/Share
|
|
Nov 30
2023
|
Seokho Bryan Yoon COO and General Counsel |
BUY
Open market or private purchase
|
Direct |
743
+3.88%
|
$2,229
$3.78 P/Share
|
|
Nov 15
2023
|
Jill M. Quigley |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
May 31
2023
|
Senthil Vel Sundaram Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,111
+17.77%
|
$2,111
$1.41 P/Share
|
|
May 31
2023
|
Seokho Bryan Yoon COO and General Counsel |
BUY
Open market or private purchase
|
Direct |
9,997
+36.15%
|
$9,997
$1.41 P/Share
|
|
May 31
2023
|
Mark J. Vignola Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
9,997
+36.15%
|
$9,997
$1.41 P/Share
|
|
Dec 23
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
137,931
+2.75%
|
$965,517
$7.25 P/Share
|
|
Dec 23
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
137,931
+2.75%
|
$965,517
$7.25 P/Share
|
|
Dec 23
2022
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
758,620
+14.88%
|
$5,310,340
$7.25 P/Share
|
|
Dec 23
2022
|
Vivo Opportunity, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
758,620
+14.88%
|
$5,310,340
$7.25 P/Share
|
|
Nov 30
2022
|
Senthil Vel Sundaram Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3
+0.04%
|
$3
$1.41 P/Share
|
|
Nov 30
2022
|
Mark J. Vignola Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
3
+0.04%
|
$3
$1.41 P/Share
|
|
Nov 30
2022
|
Seokho Bryan Yoon COO and General Counsel |
BUY
Open market or private purchase
|
Direct |
3
+0.04%
|
$3
$1.41 P/Share
|
|
Nov 23
2022
|
Lav Biosciences Fund V, L.P. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,500,000
-39.67%
|
$7,500,000
$5.5 P/Share
|
|
Sep 07
2022
|
Vivo Opportunity, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
600,000
+14.35%
|
$1,800,000
$3.6 P/Share
|
|
Sep 07
2022
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
600,000
+14.35%
|
$1,800,000
$3.6 P/Share
|
|
Aug 16
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
3,690,000
+34.35%
|
$7,380,000
$2.42 P/Share
|
|
Aug 16
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
3,690,000
+34.35%
|
$7,380,000
$2.42 P/Share
|
|
Aug 16
2022
|
Vivo Opportunity, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+33.47%
|
$3,000,000
$2.42 P/Share
|
|
Aug 16
2022
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+33.47%
|
$3,000,000
$2.42 P/Share
|
|
Aug 15
2022
|
Vivo Opportunity, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,218
+0.08%
|
$2,436
$2.99 P/Share
|
|
Aug 15
2022
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
1,218
+0.08%
|
$2,436
$2.99 P/Share
|
|
Aug 12
2022
|
Vivo Opportunity, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,123,021
+43.14%
|
$2,246,042
$2.98 P/Share
|
|
Aug 12
2022
|
Lu Hongbo Director |
BUY
Open market or private purchase
|
Indirect |
1,123,021
+43.14%
|
$2,246,042
$2.98 P/Share
|
|
May 31
2022
|
Senthil Vel Sundaram Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
7,656
+50.0%
|
$7,656
$1.47 P/Share
|
|
May 31
2022
|
Mark J. Vignola Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
7,656
+50.0%
|
$7,656
$1.47 P/Share
|